CSL Limited Publishes First Corporate Responsibility Report

MELBOURNE, Australia, March 29, 2010 - CSL Limited (ASX: CSL), Australia's leading biopharmaceutical company,
has released its first Corporate Responsibility Report, combining information
about the Company's economic, social and environmental performance for 2009.

"CSL has experienced significant growth over the past 10 years, which has
been underpinned by our commitment to conducting our business ethically and
actively contributing to the well-being of our communities," said Dr. Brian
McNamee, CEO and Managing Director of CSL Limited. "Our first Corporate
Responsibility Report is an important demonstration of this ongoing
commitment."

The report details CSL's approach to and performance in key areas of
corporate responsibility. These include the Company's research into new
medicines, its ongoing success in ensuring the safety and quality of its
broad portfolio of therapies, providing a positive and healthy work
environment for CSL employees, behaving responsibly in the global
marketplace, and providing charitable support for communities in need around
the world, while minimising the environmental impacts of its operations.

Highlights and statistics from some of these key areas include:

    - The launch of the Company's Code of Responsible Business Practice,
      setting out the standards of conduct expected of CSL employees and
      business partners
    - Continued investment totaling A$312 million in the research and
      development of protein-based medicines for the prevention and treatment
      of rare and serious human illnesses
    - A 26 percent increase in economic value distributed to the communities
      in which CSL operates, supported by 10 percent growth in the Company's
      workforce
    - Reduction of the Company's net water consumption by six percent at its
      manufacturing sites and the continued improvement of environmental
      intensity rates
    - The contribution of nearly US$10 million to patient organisations in
      the Company's therapeutic areas and the announcement of new support for
      access programs in developing countries

"As a global company, CSL recognises its role in responding to
humanitarian emergencies around the world, from pandemics to earthquakes,"
said Dr. McNamee.

"Our support programs in developing countries help address pressing
healthcare issues in our areas of expertise."

In 2009, CSL announced a US$3 million partnership with the World
Federation of Hemophilia and pledged 3 million doses of pandemic H1N1
influenza vaccine to the World Health Organization. CSL also commissioned a
study of antivenom access in Papua New Guinea and invested in new programs to
help foster the next generation of medical researchers.

About CSL

The CSL Group has a combined heritage of outstanding contribution to
medicine and human health with more than 90 years experience in the
development and manufacture of vaccines and plasma protein biotherapies.

With major facilities in Australia, Germany, Switzerland and the US, CSL
has more than 11,000 employees working in 27 countries.

For more information about CSL Limited and its 2009 Corporate
Responsibility Report, visit www.csl.com.au/.

    For further information please contact:
    Sharon McHale
    Corporate Responsibility Director
    CSL Limited
    Tel: +61-409-978-314

Sharon McHale, Corporate Responsibility Director, CSL Limited, Tel: +61-409-978-314